Vaccine to prevent cancer in people with Lynch syndrome
Lynch Vaccine
A vaccine that trains your immune system to spot common tumor mutations and help prevent colorectal and other cancers in people with Lynch syndrome.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11166709 on NIH RePORTER |
What this research studies
If you participate, researchers will use genetic sequencing of Lynch-associated adenomas and tumors to find shared mutated proteins called frameshift peptides and select the best vaccine targets. The team combines lab-grown tumor models (tumoroids), cancer cell lines, and large tumor atlases to design an off-the-shelf vaccine made from recurrent neoantigens. Earlier small human peptide vaccine trials showed strong T-cell responses and mouse models showed fewer cancers after vaccination. This program aims to advance those findings toward vaccines that could be given to people with Lynch syndrome to lower their cancer risk.
Who could benefit from this research
Good fit: People diagnosed with Lynch syndrome—especially those with colon adenomas, early-stage tumors, or otherwise at high inherited risk—are the best fit for this work.
Not a fit: People without Lynch syndrome or whose tumors lack the specific shared frameshift mutations targeted by the vaccine are unlikely to benefit.
Why it matters
Potential benefit: Could stimulate immune responses that lower the risk of colorectal and other Lynch-associated cancers.
How similar studies have performed: Prior small human peptide vaccine trials and animal studies produced robust T-cell responses and reduced tumor burden, but large prevention trials in Lynch syndrome remain new.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Blander, Julie Magarian — Weill Medical Coll of Cornell Univ
- Study coordinator: Blander, Julie Magarian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.